SCHEMBL20158752

SCHEMBL20158752

CSN1CCC(C)(C(=O)Nc2ccc(C)cn2)CC1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.50
MAPT P10636 2/20 0.50
NPC1 O15118 8/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
GAA P10253 2/20 0.42
HTT P42858 1/20 0.42
RET P07949 1/20 0.42
KDM4E B2RXH2 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ALDH1A1 P00352 1/20 0.40
TP53 P04637 1/20 0.40
GLA P06280 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20069622 0.85 RAB9A (0.54) RAB9AMAPTNPC1SMN1; SMN2GAA
SCHEMBL20148061 0.82 RAB9A (0.50) RAB9AMAPTNPC1SMN1; SMN2GAA
SCHEMBL20158751 0.79 FPR2 (0.46) RAB9AMAPTNPC1SMN1; SMN2GAA
SCHEMBL3494822 0.69 RAB9A (0.47) RAB9AMAPTNPC1SMN1; SMN2GAA
SCHEMBL2636192 0.69 RAB9A (0.78) RAB9AMAPTNPC1SMN1; SMN2GAA
SCHEMBL25668465 0.68 RAB9A (0.60) RAB9AMAPTNPC1KDM4EL3MBTL1
SCHEMBL11885434 0.68 ALDH1A1 (0.60) RAB9AMAPTNPC1SMN1; SMN2GAA
SCHEMBL423961 0.67 RAB9A (0.75) RAB9AMAPTNPC1SMN1; SMN2GAA
SCHEMBL26758519 0.67 RAB9A (0.60) RAB9AMAPTNPC1SMN1; SMN2L3MBTL1
SCHEMBL26758515 0.67 RAB9A (0.60) RAB9AMAPTNPC1SMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 RAB9A 632/4885MAPT 1499/4885NPC1 4145/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 RAB9A 632/4885MAPT 1499/4885NPC1 4145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.